Glancy Binkow & Goldberg Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit on Behalf of Investors ...
04 2월 2014 - 10:32PM
Business Wire
Glancy Binkow & Goldberg LLP reminds investors that all
purchasers of the Contingent Value Rights (“CVRs”) of Sanofi
(NASDAQ:GCVRZ) between March 6, 2012 and November 7, 2013,
inclusive (the “Class Period”), have until February 10, 2014, to
file a motion to be appointed as lead plaintiff in the shareholder
lawsuit.
Sanofi is a global healthcare company engaged in the research,
development, manufacture and marketing of healthcare products,
including pharmaceuticals and vaccines. Sanofi’s multiple sclerosis
therapy Lemtrada™ (alemtuzumab) has completed two Phase III
clinical studies and is under review for U.S. Food and Drug
Administration marketing approval in the U.S. and Europe. The
Complaint filed in the United States District Court for the
Southern District of New York alleges that the Company and certain
of its executive officers knew or recklessly disregarded but failed
to disclose that:
- Defendants’ public statements had
materially misrepresented the safety and efficacy of Lemtrada and
its prospects for FDA approval.
- The design of the Lemtrada trials
tainted the results and lowered the likelihood of FDA
approval.
- The Company lacked adequate internal
controls.
To be a member of the Class, you need not take any action at
this time; you may retain counsel of your choice or take no action
and remain an absent member of the Class. If you wish to learn more
about this action or have any questions concerning this
announcement or your rights or interests with respect to these
matters, please contact Michael Goldberg, Esquire, of Glancy Binkow
& Goldberg LLP, 1925 Century Park East, Suite 2100, Los
Angeles, California 90067, Toll-Free at (888) 773-9224, or contact
Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122
E. 42nd Street, Suite 2920, New York, New York 10168, at (212)
682-5340, by e-mail to shareholders@glancylaw.com, or visit our
website at http://www.glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CAMichael
Goldberg, 888-773-9224orGlancy Binkow & Goldberg LLP, New York,
NYGregory Linkh,
212-682-5340shareholders@glancylaw.comwww.glancylaw.com
Sanofi (NASDAQ:GCVRZ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Sanofi (NASDAQ:GCVRZ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024